FIRST AIRED: March 21, 2019

Nice work! Enjoy the show!


You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!



another blow in the race to find a treatment for Alzheimer's Biogen and its Japanese partner a sign or scrapping too late stage trials the stop testing their experimental drug for the memory robbing disease after an independent monitoring committee reported it was unlikely to succeed there are evaluating I do kind of melds effects on patients with mild cognitive impairment and mild dementia related to Alzheimer's the disease affects nearly six million Americans the news tech Biogen shares which sank more than twenty seven percent Thursday it was just two weeks ago that case I see your heart or night till expressed confidence in the drug saying it had gone through in his words the riskiest stage but a breakthrough in treating Alzheimer's has been hard to come by drug makers of experience more than one hundred failures with experimental treatments many like mark and Fizer have abandoned trials out of safety concerns or ineffectiveness Biogen however says it will not give up on its drive to develop a treatment